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Beneﬁcial modulation of the gut microbiota
P. Cotter
Teagasc Food Research Centre and APC Microbiome
Institute, Cork, Ireland
Abstract: As the scientiﬁc community continues to develop an
ever-greater understanding of the composition and function of the
human gut microbiota, and the role of speciﬁc microbial popula-
tions in health and disease, attention has turned to the tools that
are at our disposal with respect to altering these microbes in a
beneﬁcial way. The options available include the use of diet, probi-
otics/prebiotics, antimicrobials and, potentially, exercise. Here, our
recent investigations of the relationship between protein, bacteri-
ocin producing probiotics and exercise and the gut microbiota and,
in turn, health will be described.
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Rotavirus vaccines - A promise kept
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Abstract: Vaccines are now available to combat rotavirus, the
most common cause of severe, dehydrating diarrhea among chil-
dren worldwide. As of January 2016, 80 countries have introduced
rotavirus vaccines into their routine immunization programs.
High and middle income countries were the early introducers of
rotavirus vaccines and in these countries, vaccines have reduced
all-cause diarrhea and rotavirus hospitalizations by 17%-55% and
49-92%, respectively, and all-cause diarrhea deaths by 22%-50%
in some settings. Additionally, indirect protection of children age-
ineligible for rotavirus vaccine has also been observed in some high
and middle-income countries. Rotavirus vaccine introductions in
low income countries have been increasing in recent years and
early data from these settings are promising. Vaccine effective-
ness is comparable to the efﬁcacy observed in clinical trials and
the impact in high disease burden settings has been dramatic. As
rotavirus vaccines continue to rollout in low income countries, the
full range of health beneﬁts in these settings can be documented.
http://dx.doi.org/10.1016/j.ijid.2016.02.122
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Norovirus infection and vaccine development:
Where are we?
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Abstract: Noroviruses are currently recognized as the leading
cause of acute gastroenteritis outbreaks associated with contami-
nated food and/or water consumption in industrialized countries
and second to rotavirus as cause of childhood gastroenteritis. Indi-
viduals are infected many times throughout their lifetime, most of
which are asymptomatic infections with fewer episodes of mod-
erate to severely symptomatic infections which are particularly
signiﬁcant in young children living in resource-deprived countries.
Symptomatic norovirus infections are in general less severe than
rotavirus infections in children which do not preclude that severe
norovirus infections characterized by intense vomiting, watery
diarrhea and fever leading to shock and death occur worldwide.
Near 200.000 norovirus-associated deaths are estimated to occur
every year in children. Norovirus of the genogroup GII.4 have
largely predominated throughout the past years and prevention
may be possible through vaccination using virus-like particles. A
Phase I challenge study using an intramuscular bivalent GI.1/GII.4
vaccine in adults demonstrated signiﬁcant protection and Phase II
trials in children are planned for 2017.
http://dx.doi.org/10.1016/j.ijid.2016.02.123
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The outcomes of cryptosporidial infections in
Indian children
G. Kang
Christian Medical College, Vellore, India
Abstract: Cryptosporidium is an apicomplexan protozoan para-
site that has gained attention in the past two decades as a clinically
important human pathogen. The recent Global Enteric Multicen-
ter Study (GEMS) reported Cryptosporidium spp. as one of the four
top pathogens causing moderate to severe diarrhoea in children. In
India alone, we estimated cryptosporidiosis to cause 3.9 to 7.1 mil-
lion diarrhoeal episodes, 66.4 to 249 thousand hospitalizations and
5.8 to 14.6 thousand deaths in children under the age of two years.
A large proportion of children, especially those living in resource-
limited settings, are asymptomatically infected.
